MDACC Study No:2010-0191 ( NCT No: NCT01016015)
Title:A phase 2 study of temsirolimus (CCI-779, NSC 683864) and IGF-1 receptor antibody cixutumumab (IMC-A12 (NSC 742460) in patients with metastatic sarcomas
Principal Investigator:Joseph A. Ludwig
Treatment Agent:CCI-779; IMC-A12
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn about the status of
sarcoma after receiving temsirolimus and IMC-A12. The safety of this
combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Sarcoma
Phase of Study:Phase II
Treatment Agents:CCI-779
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:National Cancer Institute's Cancer Therapy Evaluation Program (CTEP)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Joseph A. Ludwig
Dept:Sarcoma Medical Oncology
For Clinical Trial Enrollment:713-792-3626
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults